Evidence map›Paper›PMID 21203627›Full record

ArticleChemical communications (Cambridge, England)2011

A cross-over inhibitor of the botulinum neurotoxin light chain B: a natural product implicating an exosite mechanism of action.

Nicholas T Salzameda, Lisa M Eubanks, Joseph S Zakhari, Kyoji Tsuchikama, Nicholas J DeNunzio, Karen N Allen, Mark S Hixon, Kim D Janda

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chemical communications (Cambridge, England), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 17 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Nicholas T SalzamedaDepartment of Chemistry, and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA.
Lisa M Eubanks
Joseph S Zakhari
Kyoji Tsuchikama
Nicholas J DeNunzio
Karen N Allen
Mark S Hixon
Kim D Janda
Scripps Research Institute · USBoston University · USTakeda (United States) · US

Funding

Investigations Targeting Symptomatic Relief to Botulinum Neurotoxin A IntoxicatioR01AI080671 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI JANDA, KIM · 2009 to 2013
$2.2M
GENETICS AND ROLE OF ALGINATE IN P. AERUGINOSA INFECTIONR29AI030050 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI GOLDBERG, JOANNA B. · 1991 to 1995
–
NIAID NIH HHS AI080671NIAID NIH HHS N01 AI030050NIAID NIH HHS N01-AI30050NIAID NIH HHS R01 AI080671
6 · The paper itself

Abstract

Clostridium botulinum produces the most lethal toxins known to man, as such they are high risk terrorist threats, and alarmingly there is no approved therapeutic. We report the first cross-over small molecule inhibitor of these neurotoxins and propose a mechanism by which it may impart its inhibitory activity.

Indexed as

Amino Acid SequenceBiological ProductsBotulinum ToxinsCaffeic AcidsCatalytic DomainClostridium botulinumCross-Linking ReagentsFluorescence Resonance Energy TransferHIV Integrase InhibitorsHumansMaleMolecular Sequence DataNeurotoxinsSubstrate SpecificitySuccinatesSynaptosomal-Associated Protein 25Biological ProductsBotulinum ToxinsCaffeic Acidschicoric acidCross-Linking ReagentsHIV Integrase InhibitorsNeurotoxinsSuccinatesSynaptosomal-Associated Protein 25Vesicle-Associated Membrane Protein 2

Identifiers

PMID21203627
PMCPMC3065946
OpenAlexW2166537394

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.